Skip to main content
. 2021 Dec 13;82(1):55–62. doi: 10.1007/s40265-021-01650-7

Fig. 2.

Fig. 2

Most common (≥ 10% of ofatumumab recipients) treatment-emergent adverse events in the safety population of two identical phase III trials (ASCLEPIOS I and II) in patients with relapsing forms of multiple sclerosis [20].